You are here: Industry Insights > BioNTech

News List

AGC Biologics Supports Omicron-based Vaccine Candidate Manufacturing contractpharma
February 09, 2022
Global CDMO’s Heidelberg facility supplies more pDNA material to help address growing needs.
Pfizer and BioNTech initiate study to evaluate Omicron-based COVID-19 vaccine in adults 18 to 55 years of age WorldPharmaNews
January 28, 2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate in healthy adults 18 through 55 years of age.
Japan approves Pfizer-BioNTech’s Covid-19 vaccine for children Pharmaceutical-Technology
January 24, 2022
The vaccine doses that will be administered for children will use one-third of a dose given for adults.
BioNTech, Crescendo Biologics to Develop Multi-Specific Precision Immunotherapies contractpharma
January 11, 2022
Crescendo will contribute its transgenic platform to deliver fully human heavy-chain antibody domains against targets nominated by BioNTech.
Pfizer and BioNTech sign new global collaboration agreement to develop first mRNA-based shingles vaccine WorldPharmaNews
January 07, 2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles...
Pfizer and BioNTech enter deal to develop first mRNA vaccine for shingles Pharmaceutical-Technology
January 07, 2022
Pfizer and BioNTech have entered a new research, development and marketing partnership for a potential first mRNA-based vaccine to prevent shingles (herpes zoster virus (HZV)).
Pfizer and BioNTech receive U.S. FDA Emergency Use Authorization of COVID-19 vaccine booster for individuals 12 years of age and older WorldPharmaNews
January 05, 2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) of a booster dose...
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply AmericanPharmaceuticalReview
December 22, 2021
Pfizer Inc. and BioNTech SE announced an agreement has been reached with the European Commission (EC) and its member states to exercise an option to purchase more than 200 million additional doses of COMIRNATY®...
EU to procure over 200 million doses of Pfizer-BioNTech’s Comirnaty Pharmaceutical-Technology
December 22, 2021
Pfizer and BioNTech have signed an agreement under which the European Commission (EC) and its member states will procure over 200 million additional doses of the companies’ Covid-19 vaccine Comirnaty.
Pfizer Vaccine Disappoints in Kids Ages 2 to 5 Drugs
December 20, 2021
Two doses of a pediatric Pfizer-BioNTech COVID-19 vaccine failed to spur an adequate immune response in children aged 2 to 5, the companies announced Friday.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page